Apc Mutation Enhances PyMT-Induced Mammary Tumorigenesis by Prosperi, Jenifer R. et al.
Apc Mutation Enhances PyMT-Induced Mammary
Tumorigenesis
Jenifer R. Prosperi
1, Andrey I. Khramtsov
2, Galina F. Khramtsova
2, Kathleen H. Goss
1*
1Department of Surgery, University of Chicago, Chicago, Illinois, United States of America, 2Department of Medicine, University of Chicago, Chicago, Illinois, United
States of America
Abstract
The Adenomatous Polyposis Coli (APC) tumor suppressor gene is silenced by hypermethylation or mutated in up to 70% of
human breast cancers. In mouse models, Apc mutation disrupts normal mammary development and predisposes to
mammary tumor formation; however, the cooperation between APC and other mutations in breast tumorigenesis has not
been studied. To test the hypothesis that loss of one copy of APC promotes oncogene-mediated mammary tumorigenesis,
Apc
Min/+ mice were crossed with the mouse mammary tumor virus (MMTV)-Polyoma virus middle T antigen (PyMT) or
MMTV-c-Neu transgenic mice. In the PyMT tumor model, the Apc
Min/+ mutation significantly decreased survival and tumor
latency, promoted a squamous adenocarcinoma phenotype, and enhanced tumor cell proliferation. In tumor-derived cell
lines, the proliferative advantage was a result of increased FAK, Src and JNK signaling. These effects were specific to the
PyMT model, as no changes were observed in MMTV-c-Neu mice carrying the Apc
Min/+ mutation. Our data indicate that
heterozygosity of Apc enhances tumor development in an oncogene-specific manner, providing evidence that APC-
dependent pathways may be valuable therapeutic targets in breast cancer. Moreover, these preclinical model systems offer
a platform for dissection of the molecular mechanisms by which APC mutation enhances breast carcinogenesis, such as
altered FAK/Src/JNK signaling.
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Introduction
Mutation of the Adenomatous Polyposis Coli (APC) tumor suppressor
has been implicated in breast cancer; yet how it cooperates with
oncogenic events to drive breast cancer pathogenesis is unknown.
Numerous studies have demonstrated APC mutationorlossinhuman
sporadic breast cancer (reviewed in [1]). APC inactivation has been
reported in 5–70% of tumors, varying widely because of power
constraints, the type of analysis performed, and specific molecular
subtypes examined (reviewed in [1]). Unlike colorectal cancer where
mutation is the primary mechanism for APC loss, APC expression is
frequently down-regulated through transcriptional silencing via gene
promoter methylation in breast cancer. For example, APC promoter
hypermethylation has been observed in approximately 70% of
inflammatory human breast tumors [2] and in 7% of metaplastic
breast carcinomas [3]. APC promoter methylation also correlates with
decreased disease-free and overall survival [4], providing evidence
that APC down-regulation is not a passive bystander but, rather,
contributes significantly to breast cancer.
Mouse models have further supported the importance of APC
in breast cancer. Female mice carrying a germline heterozygous
nonsense mutation in Apc, designated Apc
Min/+, develop spontane-
ous and carcinogen- or radiation-induced mammary tumorigen-
esis, although spontaneous mammary tumors develop at a low
frequency [5,6,7]]. Our laboratory demonstrated that mammary
hyperplasia and squamous metaplasia are common in Apc
Min/+
mice, and APC is required for normal lobuloaloveolar develop-
ment during pregnancy and lactation [8]. Other alleles, including
Apc
1638, also develop spontaneous mammary tumors and are
sensitive to radiation or chemical carcinogens [9,10]. Spontaneous
tumors in Apc
D474 mice resemble squamous cell carcinomas [11], a
pathological phenotype that has been observed often in mammary
tumors in which Wnt/b-catenin signaling is aberrantly activated
[12]. While whey acidic protein (WAP)- and b-lactoglobulin-cre-
induced Apc deletion increased squamous metaplasias [13,14],
keratin-14 (K-14)-mediated Apc deletion led to mammary tumor
formation [14], suggesting that the cell type in which APC is
inactivated is critical for the associated phenotypes. Recently,
truncation at codon 1572 in APC (Apc
1572T) was shown to be
sufficient for metastatic mammary tumors that resemble human
metaplastic breast cancers [15].
It is now appreciated that most breast cancers contain more
than 80 non-silent mutations [16]. These tumor models have
addressed the importance of Apc mutation or deletion alone in
mammary tumor initiation, but not the contribution of APC loss in
the context of other oncogenic events. In this study, we addressed
how Apc mutation cooperates with known breast cancer oncogenes
to mimic more closely human sporadic breast cancer using mouse
models. MMTV-PyMT transgenic females develop metastatic
mammary tumors with high penetrance [17]. Despite the rapid
development of aggressive tumors using this model, multiple
studies have demonstrated the ability to enhance tumorigenesis
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follows a pattern similar to human sporadic breast cancer [21].
Further, signaling pathways activated downstream of PyMT
overexpression, including the Src family of kinases, are commonly
dysregulated in human breast cancers [22]. MMTV-c-Neu
mammary tumors mimic HER2-positive human breast cancer
and develop with lower penetrance and significantly longer latency
[23]. The current study demonstrates that Apc mutation enhances
PyMT-, but not Neu- induced mammary tumorigenesis, where it
drives the squamous adenocarcinoma phenotype and provides a
significant proliferation advantage. Importantly, these differences
are associated with increased signaling through the FAK/Src/
JNK network. These data support a model in which APC mutation
may promote breast cancer by cooperating with other oncogenic
changes to alter their histopathological and growth characteristics
via the activation of signaling pathways downstream of cell-matrix
interactions.
Methods
Ethics Statement
All procedures were performed with prior approval (protocol
#71828) from the University of Chicago Institutional Animal
Care and Use Committee, which has full accreditation from the
Association for Assessment and Accreditation of Laboratory
Animal Care.
Mice
The MMTV-PyMT (line #634) and MMTV-c-Neu (line #202)
transgenic mice were obtained from the Mouse Models of Human
Cancers Consortium at the National Cancer Institute on a FVB/N
background. Apc
Min/+ mice (The Jackson Laboratory, Bar Harbor,
ME), maintainedona C57Bl/6background,werebackcrossed onto
FVB/N to the N6 generation resulting in Apc
Min/+ mice expected to
be .90% derived from FVB/N. Female Apc
Min/+ (FVB/N) mice
were crossed to male MMTV-PyMT or MMTV-c-Neu mice to
generate experimental (MMTV-PyMT;Apc
Min/+ or MMTV-c-
Neu;Apc
Min/+) and age-matched control (MMTV-PyMT;Apc
+/+ or
MMTV-c-Neu;Apc
+/+)N 6F1 virgin females. Numbers of animals
used for each experiment are specified in the figure legends.
Analysis of mammary tumors and lung metastases
Mice were checked bi-weekly for palpable mammary tumors, and
tumors were measured with calipers every other day. Tumor volume
was calculated using the equation (mm
3)=(a
26b)/2. For the survival
study, animals were euthanized when tumors became ulcerated or
tumor size reached 10% of body weight. Animals were injected with
75 mg/kg 5-bromo-2-deoxyuridine (BrdU, BD Biosciences, San
Diego, CA) two hours prior to euthanasia at which time primary
mammary tumors were harvested, cultured (see below) or fixed in
3.7% formaldehyde. Overt metastases were quantitated by visual
inspection after the lungs were inflated with 3.7% formaldehyde.
Surface lung metastases (.1 mm) were counted using a dissection
microscope at 1.66magnification. Paraffin-embedded sections were
stained with hematoxylin and eosin (H&E) and evaluated by two
individual blinded pathologists (AK and GK). Lungs were sectioned,
stained with H&E, and examined for micrometastases (10–100
tumor cells) by a blinded observer (LQ) using 15 sections from each
animal (n=5 per genotype).
LOH analysis of Apc
Genomic DNA was isolated from two 4 mm-paraffin-embedded
sections of tumors and normal mammary gland from Apc
Min/+ mice
as previously described [24]. A 156-bp fragment of the Apc gene was
amplified using the PCR conditions as described by Luongo et al
[25]. PCR products were then digested with HindIII to differentiate
the 123-bp wildtype and 144-bp Apc
Min alleles, and products were
subjected to agarose gel electrophoresis (4% agarose) as described
[25,26]. Band intensity was quantified using NIH ImageJ software;
data are presented as a ratio of WT:Min alleles.
Immunohistochemistry (IHC) and immunofluorescence
(IF)
IHC for total b-catenin was performed and quantified as described
previously [27]. For IF, tissues were blocked with 0.2% nonfat dried
milk, 2% bovine serum albumin and 0.3% Triton X-100 in PBS for
30 min. For in vitro IF studies, cells were fixed with 3.7% formaldehyde
and permeabilized with 0.3% Triton X-100 for 15 min prior to
staining with the following primary antibodies diluted 1:400 in
blocking buffer: anti-BrdU rat monoclonal antibody (Abcam, cat#
6326, Cambridge, MA); anti-b-catenin rabbit polyclonal antibody
(Lab Vision Products, cat# RB-9035); anti-E-cadherin mouse
monoclonal antibody (BD Biosciences, cat# 610181); or anti-p-
FAK mouse monoclonal antibody (Santa Cruz Biotechnology, cat#
sc-81493, Santa Cruz, CA). Expression was detected using conjugated
secondary antibodies (1:200 each; Invitrogen, Carlsbad, CA). For
visualization of F-actin, cells were co-stained with fluorescently
conjugated Phalloidin (Invitrogen). Slides were mounted with
Fluoromount G with Hoechst. Terminal deoxynucleotidyl transferase
biotin-dUTP nick end labeling (TUNEL) assays were performed using
the ApopTag Plus Peroxidase in Situ Apoptosis Detection Kit
(Chemicon, Temecula, CA). For quantification, at least 200 cells
were counted per tissue section, and sections from one tumor per
mouse (n=5 per genotype) were analyzed at each time point. The
percentage of positive cells was averaged, and statistical analyses were
performed using a Student’s t-test.
Cell culture and in vitro proliferation assay
Primary tumors were rinsed in sterile phosphate buffered saline
(PBS), minced, and plated in RPMI media with 10% FBS and 1%
penicillin/streptomycin. After two days, the media was changed
and cells were routinely passaged using 0.25% trypsin/EDTA. For
analysis, all cells were between 20–30 passages, and morphology
was monitored by phase-contrast microscopy. SW480 cells
(ATCC, Manassas, VA), used as a positive control for reporter
assays, were grown in DMEM with 10% FBS and 1% penicillin/
streptomycin. 1610
5 cells were plated in 12-well plates for 24 h
prior to the addition of 10 mM BrdU and treated with either
50 mM PP2 (Sigma, St. Louis, MO), 20 or 30 mM SP600125
(Sigma), a combination of PP2 and SP600125, or DMSO as a
control. After 12 h, cells were fixed in 3.7% formaldehyde, and
BrdU IF was performed as described above.
Western blot analysis
Total protein was isolated from tumor-derived cell lines using
lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% NP-40,
1.0 mM EDTA, 0.2 mM PMSF, and 16 protease inhibitor
cocktail (Fisher, Pittsburgh, PA)). 20 mg of protein was separated
by SDS-PAGE (10% gel), and transferred onto Immobilon-P
membrane (Fisher). Membranes were blocked for 1 hr in 16TBS
with 0.1% Tween 20 and 5% nonfat dried milk, followed by
overnight incubation with primary antibodies diluted 1:1000 in
TBST with 1% BSA (b-actin – Sigma, cat# A1978; Src (cat#
2108), p-Src (cat# 2101), JNK (cat# 9252), and p-JNK (cat#
4668)– Cell Signaling, Danvers, MA; FAK – BD Biosciences, cat#
610087; p-FAK – Santa Cruz Biotechnology, cat# sc-81493).
Secondary antibody (anti-mouse or anti-rabbit IgG-HRP, 1:2000)
APC and PyMT cooperate in Breast Cancer
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and blots were developed using the Immun-Star HRP kit
(BioRad). Representative blots are shown from 3 experiments.
b-catenin/TCF reporter assays
Cells were plated in triplicate and transfected using Lipofecta-
mine 2000 (Invitrogen) with either pTOPflash or pFOPflash as
previously described [28], and co-transfected with pRL-TK
(Renilla luciferase-thymidine kinase; Promega, Madison, WI).
Lysates were harvested after 48 h and analyzed using the Dual
Luciferase Assay System kit (Promega). Luciferase activity was
normalized for transfection efficiency and FOPflash activity; the
mean of 3 independent experiments is shown.
Statistical analysis
Kaplan-Meier curves were generated for tumor latency and
survival analysis, and statistical significance was determined using
the Wilcoxon test. Differences in tumor type and grade, as well as
b-catenin localization, were analyzed using the Fisher’s exact test.
For tumor size, an exact binomial goodness-of-fit test was
performed. Student’s t-test was used for statistical analysis of all
remaining studies.
Results
Apc
Min/+ mutation decreases mammary tumor latency
and survival in the PyMT model
The Apc
Min allele was backcrossed onto FVB/N to the N6
generation resulting in Apc
Min/+ mice expected to be .90%
derived from FVB/N and found to live more than a year without
severe intestinal complications. In the timeframe of the current
studies, Apc
Min/+ (FVB/N) females do not develop spontaneous
mammary tumors and were used for breeding with MMTV-
PyMT or MMTV-c-Neu transgenic males. Despite the aggressive
nature of MMTV-PyMT mammary tumorigenesis, heterozygosity
of Apc resulted in a significant decrease in the median survival time
of 91 days as compared to 104 days in the MMTV-PyMT;Apc
+/+
mice (Figure 1A; p=0.0006). In addition, the MMTV-PyMT;
Apc
Min/+ females developed tumors earlier than control animals
such that the median latency was decreased from 55 to 48 days
(Figure 1B; p=0.0009). To determine whether this was a specific
effect on PyMT-mediated mammary tumorigenesis, we assessed
whether Apc
Min heterozygosity would impact MMTV-c-Neu-
driven tumor development using an identical approach. Interest-
ingly, Apc mutation did not significantly impact MMTV-c-Neu
tumor latency or survival (Figure 1C and D).
The Apc
Min/+ mutation alters PyMT tumor histopathology
Given that Apc mutation reduced overall animal survival in this
initial study, tumorigenesis was then analyzed at 65 days of age to
investigate early changes mediated by APC. All of the tumors (7/7)
analyzed from the MMTV-PyMT;Apc
+/+ animals were identified
as solid carcinomas (Figure 2A; H&E staining shown in
Figure 2B); however, more than 50% of the MMTV-PyMT;
Apc
Min/+ tumors (5/9) were classified as squamous adenocarcino-
mas (Figure 2A,p ,0.05 with Fisher’s exact test; H&E staining
shown in Figure 2C). Despite this significant change, Apc
heterozygosity did not affect the histopathology of MMTV-c-Neu
Figure 1. Apc heterozygosity accelerates MMTV-PyMT-mediated mammary tumorigenesis with no effect in the MMTV-c-Neu model.
Experimental (MMTV-PyMT;Apc
Min/+ (n=35 for survival and n=13 for latency) and MMTV-c-Neu;Apc
Min/+ (n=13)) and control (MMTV-PyMT;Apc
+/+
(n=37 for survival and n=15 for latency) and MMTV-c-Neu;Apc
+/+ (n=15)) mice were palpated bi-weekly for tumor development. For the survival
study, animals were sacrificed when the tumor reached 10% of the animal’s body weight or became ulcerated. Kaplan-Meier curves for MMTV-PyMT
tumor studies demonstrate that both (A) survival and (B) latency have a significant shift to the left in the presence of the Apc
Min/+ mutation. However,
Kaplan-Meier curves for (C) survival and (D) latency show no change in the MMTV-c-Neu model with introduction of the Apc
Min/+ mutation. Median
values are given, and significance was determined using the Wilcoxon test.
doi:10.1371/journal.pone.0029339.g001
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mice per genotype; data not shown). Although there was not a
significant increase in the mean tumor burden in the MMTV-
PyMT;Apc
Min/+ mice, significantly more MMTV-PyMT;Apc
Min/+
mice (10/21) had tumor burden (i.e. total tumor volume per mouse)
greater than the mean tumor burden (977.66212 mm
3)f o rt h e
MMTV-PyMT;Apc
+/+ control mice at 65 days of age (Figure 2D;
p#0.05 by exact binomial goodness-of-fit test). No difference was
observed in the average tumor number per mouse as MMTV-
PyMT;Apc
Min/+ mice had 4.6 tumors/animal (n=21) and MMTV-
PyMT;Apc
+/+ mice had 3.8 tumors/animal (n=18; p=0.138).
Moreover, neither overt (.1 mm) nor micro (10–100 cells) lung
metastases were significantly affected by Apc mutation in either
model (not shown).
A key step in intestinal tumorigenesis in Apc
Min/+ mice is loss of
heterozygosity (LOH) of Apc, occurring in nearly 100% of tumors
[25]. Therefore, we addressed whether mammary tumors isolated
from MMTV-PyMT;Apc
Min/+ mice exhibited LOH of the wildtype
Apc allele. Comparison of genomic DNA isolated from normal
Apc
Min/+ mammary tissue using a PCR-based assay followed by
quantification of the ratio of Apc
+ to Apc
Min alleles demonstrated
that mammary tumors from MMTV-PyMT;Apc
Min/+ mice
generally retain the wildtype allele (Figure S1), suggesting that
haploinsufficiency for Apc promotes tumor development in the
MMTV-PyMT model.
Proliferation and apoptosis are altered in MMTV-
PyMT;Apc
Min/+ mammary tumors
To identify the cellular basis for decreased tumor latency and
survival in MMTV-PyMT;Apc
Min/+ mice, tumor cell apoptosis and
proliferation wereanalyzed.Ofnote,tumors of both solid carcinoma
and squamous adenocarcinoma phenotype were analyzed for
subsequent studies.Proliferation inprimarytumorsfrom the survival
study and at 65 days was measured by BrdU incorporation. We
observed a statistically significant two-fold increase in the percentage
of BrdU-positive cells in Apc-mutant mice (19.7% vs. 9.9% in control
tumors; Figure 3A–C;p ,0.05). In addition, TUNEL staining
demonstrated a two-fold decrease in apoptotic cells in tumors from
the MMTV-PyMT;Apc
Min/+ mice compared to control animals
(3.5% compared to 7.5% in controls; Figure 3D–F;p ,0.05).
Collectively, these data indicate that APC inactivation enhances
PyMT-mediated mammary tumorigenesis by simultaneously driving
tumor cell proliferation and attenuating apoptosis.
Figure 2. The Apc
Min mutation alters the histopathology of MMTV-PyMT mammary tumors and enhances tumor volume. Tumors
were fixed, embedded and stained with H&E. Quantification of the histopathological classification demonstrates that more tumors from MMTV-
PyMT;Apc
Min/+ (n=9) mice display a squamous adenocarcinoma phenotype rather than solid carcinomas in control animals (n=7) (A,p ,0.05 using
Fishers exact test). Representative images of H&E-stained MMTV-PyMT;Apc
+/+ tumors showing development of solid carcinomas (B). In contrast,
tumors from the MMTV-PyMT;Apc
Min/+ mice were predominately classified as squamous adenocarcinomas (C). Scale bar=100 mm. (D) At 65 days of
age, there was an increase in the number of MMTV-PyMT;Apc
Min/+ (n=21) mice with a greater total tumor volume than the mean of the control
animals (n=18) (p,0.05 using exact binomial test goodness-of-fit).
doi:10.1371/journal.pone.0029339.g002
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by Apc mutation in MMTV-PyMT mammary tumors
In colorectal cancer and other tumor types, APC inactivation is
frequently associated with nuclear and cytosolic accumulation of b-
catenin as a measure of canonical Wnt pathway activation [29]. To
determine if APC mutation promoted mammary tumorigenesis via
Wnt/b-catenin pathway stimulation, we next compared the
subcellular localization of b-catenin in mammary tumors isolated
from MMTV-PyMT;Apc
+/+ and MMTV-PyMT;Apc
Min/+ mice
(Figure S2). In mammary tumors isolated from both genotypes,
the majority of tumors maintained some b-catenin localization at the
cellmembrane. 2/4 (50%) of tumorsfrom the MMTV-PyMT;Apc
+/+
mice demonstrated high levels (i.e. IHC score of 2 or 3) of either
cytosolic or nuclear b-catenin, suggesting that these tumors show
some basal Wnt/b-catenin pathway activity (Figure S2A). All
MMTV-PyMT;Apc
Min/+ tumors (5/5) had high levels of cytosolic or
nuclear b-catenin (Figure S2A) but a difference between genotypes
was not statistically significant (p=0.17 using Fisher’s exact test).
Analysis of the mRNA and protein expression of b-catenin target
genes, cyclin D1, axin2, and c-myc,i nt u m o r sa l s od i dn o ts h o wa n y
difference between the two genotypes, although the expression of
these genes were already significantly elevated in all of the tumors
compared to normal mammary gland (not shown). These data
suggest that Apc mutation does not induce Wnt/b-catenin pathway
signaling over basal levels in MMTV-PyMT tumors.
MMTV-PyMT;Apc
Min/+ tumor cells have altered
morphology, proliferation, and signaling through the
FAK/Src/JNK pathway
To identify the molecular mechanisms downstream of APC
mutation responsible for promoting mammary tumorigenesis in
the PyMT model, tumor cells were cultured from animals from
each genotype. Two lines from each genotype were thoroughly
characterized, although only one of each genotype is shown for
space considerations (data from the second set is shown in Figure
S3). IF for b-catenin demonstrated exclusive localization at cell-
cell junctions in the MMTV-PyMT;Apc
+/+ tumor cells
(Figure 4A). In the MMTV-PyMT;Apc
Min/+ cells, b-catenin was
localized to cell-cell contacts as well as in punctate clusters in the
cytosol or membrane; however, nuclear b-catenin localization was
not observed (Figure 4A). This pattern of b-catenin was also
coincident with a pronounced spread morphology in the MMTV-
PyMT;Apc
Min/+ cells with fewer cell-cell interactions and more
extensive lamellipodia (Figure 4A). This is in contrast to the more
epithelial, cobblestone morphological appearance of the MMTV-
PyMT;Apc
+/+ cells (Figure 4A). To assess active Wnt/b-catenin
signaling, b-catenin/TCF reporter assays were performed in
which cells were transiently transfected with a plasmid expressing
multiple TCF-binding sites upstream of firefly luciferase (TOP-
flash) and normalized using a co-transfected renilla luciferase
plasmid. Transfection with a plasmid containing mutant TCF sites
(FOPflash) controlled for specificity. Both sets of tumor cells had
very low basal reporter activity compared to the SW480 colorectal
carcinoma cell line that carries an APC mutation, and no
significant difference was observed between the cell lines
(Figure 4B). Both types of tumor cells, however, were able to
respond to pathway induction using exogenous Wnt ligand (not
shown), suggesting that their low basal activity was not due to
some selective inability to induce signaling.
To further investigate the morphological changes observed in
the MMTV-PyMT;Apc
Min+ cells, focal adhesion morphology and
distribution were analyzed. Localization of active, autopho-
Figure 3. Introduction of Apc
Min/+ mutation promotes tumor cell proliferation and decreases apoptosis in MMTV-PyMT tumors.
Animals were injected with BrdU 2 h prior to sacrifice and tumor sections were stained with an anti-BrdU antibody (red) to assess incorporation as a
measure of S-phase entry. Nulcei were counterstained with Hoechst (blue). Apoptosis was quantified using TUNEL staining on tumor sections
(brown); the tissues were counterstained with hematoxylin. Representative images of (A and D) MMTV-PyMT;Apc
+/+ (n=12) and (B and E) MMTV-
PyMT;Apc
Min/+ (n=10) tumors are shown. Average percent BrdU incorporation (C) or percent TUNEL-positive cells (F) from both the survival and day
65 studies combined with standard error of the mean (SEM) shown. Scale bars=20 mm for BrdU and 100 mm for TUNEL. *p,0.05 using a two-sided
Student’s t-test.
doi:10.1371/journal.pone.0029339.g003
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adhesions, was predominantly confined to the rounded cell
perimeter of MMTV-PyMT;Apc
+/+ tumor cells (Figure 4C). In
contrast, many of the MMTV-PyMT;Apc
Min/+ cells had phospho-
FAK localized at the ends of the actin stress fibers in an elongated,
plaque-like distribution pattern. The expanded lamellipodia
and branched actin networks are especially apparent in the
IF images of the phalloidin-stained MMTV-PyMT;Apc
Min/+ cells
(Figure 4C). The enhanced spreading and pronounced focal
adhesions in the cells carrying an Apc mutation was also consistent
with a significant increase in phospho-FAK (Tyr397) in lysates
from the MMTV-PyMT;Apc
Min/+ tumor cells by western blotting
(Figure 5A). In addition, tumors from MMTV-PyMT;Apc
Min/+
mice showed more robust phospho-FAK (Tyr397) staining by IF
than control tumors (Figure S3E).
One well-characterized consequence of PyMT overexpression
in mammary tumorigenesis is activation of the Src family of
kinases (reviewed in [22]). Additionally, Src is activated by FAK at
focal adhesions (reviewed in [30]). As expected, Src activity,
measured by phosphorylation at Tyr416, was detectable in
MMTV-PyMT;Apc
+/+ tumor cells; yet, in the presence of the
Apc
Min/+ mutation, phosphorylated Src was significantly up-
regulated (Figure 5A). Because interactions between FAK and
Src can activate the mitogen-activated protein kinase (MAPK), c-
Jun N-terminal kinase (JNK) [30], JNK phosphorylation was
examined. Like phospho-FAK and phospho-Src, an increase in
phosphorylated (Thr183/Tyr185) JNK was observed in the
MMTV-PyMT;Apc
Min/+ cells compared to control cells, which
showed very little JNK activity (Figure 5A). Although total Src
and JNK are increased slightly in the MMTV-PyMT;Apc
Min/+
tumor cells, this does not solely account for the increase in
phosphorylated protein.
The FAK/Src/JNK signaling pathway is implicated in
regulating proliferation downstream of cell-matrix interactions
[31,32]. Therefore, we speculated that increased Src or JNK
activation might be responsible for the elevated proliferation in
tumors from MMTV-PyMT;Apc
Min/+ mice. To confirm that the
tumor cells maintained the proliferative advantage of the primary
tumors, MMTV-PyMT;Apc
Min/+ cells were analyzed and showed
an increased level of BrdU incorporation (91% vs 68% in the
control cells; *p,0.05; Figure 5B). Next, the experimental and
control cells were treated either with a JNK inhibitor, SP600125, a
Src inhibitor, PP2, or a combination of both. The Src inhibitor or
the combination resulted in a significant decrease of proliferation
Figure 4. Cell lines generated from tumors have similar phenotypes to primary tumors. Primary cells were isolated from mammary
tumors from MMTV-PyMT;Apc
+/+ and MMTV-PyMT;Apc
Min/+ mice. (A) IF with a b-catenin antibody (green) and E-cadherin (red) antibody shows
restricted localization of both proteins to cell-cell contacts in the control cells (left panel). In the Apc-mutant cells (right panel), junctional b-catenin
and E-cadherin are observed but b-catenin is also localized in a punctate pattern in the cytosol or membrane. No nuclear accumulation of b-catenin is
observed. Nuclei are stained with Hoechst (blue). Scale bars=20 mm. (B) b-catenin/TCF reporter assays showed minimal basal Wnt/b-catenin pathway
activation in both cell lines. SW480 cells were used as a positive control. The data are shown as a ratio of normalized TOPflash:FOPflash values. (C)I F
staining with phalloidin to label F-actin (green) illustrates a more spread morphology with extensive lamellipodia formation for the MMTV-
PyMT;Apc
Min/+ tumor cells (bottom panels) compared to the control cells (top panels). In addition, phospho-FAK (Tyr397, red) localizes in plaques
primarily at the lamellipodia along actin stress fibers. Nuclei are stained with Hoechst (blue). Scale bars=20 mm.
doi:10.1371/journal.pone.0029339.g004
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PyMT;Apc
Min/+ cells (91%; *p,0.05; Figure 5B). In fact, BrdU
incorporation in the MMTV-PyMT;Apc
Min/+ cells after PP2 or
PP2/SP600125 treatment was statistically equivalent to the
MMTV-PyMT;Apc
+/+ control cells without any treatment (68%;
Figure 5B), suggesting that hyperactivation of Src and JNK
signaling are partially responsible for the increased proliferation
observed in the MMTV-PyMT;Apc
Min/+ cells. Consistent with the
known basal activation of Src in MMTV-PyMT tumors ([33] and
reviewed in [22]), proliferation was also decreased in control cells
using both PP2 and the combination of PP2/SP600125 (data not
shown). At the dose used here, the JNK inhibitor had no effect on
proliferation of the MMTV-PyMT;Apc
Min/+; however, the JNK
inhibitor could significantly suppress proliferation at higher doses
(Figure 5B). These results, taken together, suggest that one
mechanism by which APC mutation promotes mammary tumor
cell proliferation in the PyMT model is through activation of Src
and JNK signaling downstream of FAK and enhanced tumor cell-
matrix interactions.
Discussion
We have demonstrated that Apc mutation cooperates with the
PyMT oncogene to significantly accelerate mammary tumorigen-
esis and alter the tumor histopathology. It was unexpected that the
effect of APC mutation would be specific to the MMTV-PyMT
mammary tumor model. In fact, we had predicted that the
MMTV-c-Neu model, which has a longer tumor latency and
lifespan than MMTV-PyMT mice, might be more sensitive to the
Apc
Min/+ mutation. Few studies have shown disparate effects in
tumor development in the MMTV-c-Neu and MMTV-PyMT
transgenic models. For example, MUC1 deficiency significantly
attenuated PyMT tumorigenesis but had no effect on Neu-induced
tumors [34,35]. Because MUC1 localization is disrupted in
mammary glands from Apc
Min/+ females [8], we investigated
MUC1 expression in the PyMT animals but detected no difference
(J.R.P., K.H.G., unpublished results). While a number of
similarities between MMTV-PyMT and MMTV-c-Neu tumor
models exist, there are also several important differences (reviewed
in [36]). A wide array of pathways are activated downstream of
PyMT, including PI3K and Shc, but most involve direct activation
of Src kinases [22]. Activation of c-Src is required for PyMT-
mediated tumorigenesis [33] but does not appear to be critical
downstream of Neu [37]. Neu overexpression activates many
signaling networks, including the PI3K and Wnt/b-catenin
pathways (reviewed in [38,39]). One possible explanation for
oncogene-specific effects of Apc-mutation on tumorigenesis is that
redundant signaling is activated by Neu expression and Apc
mutation. We observed that Src was hyperactivated the MMTV-
PyMT;Apc
Min/+ tumor cells, and this up-regulation was not due to
elevated levels of PyMT itself in the Apc
Min/+ tumors (J.R.P.,
K.H.G., unpublished results). Modifiers that impact mammary
tumor development in the Apc
Min/+ mice and influence PyMT-
mediated tumorigenesis have been identified and mapped [40].
However, genetic background and the presence of such modifiers
are not likely to be confounding factors in our studies since 1) both
transgenic alleles were on FVB/N background, 2) the same
backcrossed Apc
Min/+(FVB) animals were used for breeding to both
models, and 3) genetically matched controls were used for all
analyses. Another unexpected finding was that Apc mutation did
not impact lung metastases in either tumor model. Recently, APC
deletions and nuclear b-catenin accumulation were linked to brain
metastases [41], and Wnt signaling was implicated in breast cancer
metastasis to the lung, brain and bone [42,43,44]. Mammary
tumors in the Apc1572T genetic model are highly metastatic to the
lung [15]. It is possible that the short tumor latency and survival in
the PyMT model precluded us from observing a significant effect
on lung metastasis or that the cooperative signaling pathways
downstream of Apc mutation and PyMT or Neu involved in
primary tumor development are distinct from metastasis media-
Figure 5. Increased cell proliferation in Apc-mutant tumor cells is dependent on active Src and JNK signaling. (A) Western blotting was
performed on total cell lysates from the tumor cell lines with antibodies to detect total and phosphorylated forms of JNK, FAK and Src. Increased
phosphorylation of JNK, FAK, and Src is observed in the MMTV-PyMT;Apc
Min/+ tumor cells compared to control cells. Actin was used as a loading
control. (B) Tumor cell proliferation was assessed using BrdU incorporation and staining with an anti-BrdU antibody. Quantification shows that,
consistent with the in vivo studies, MMTV-PyMT;Apc
Min/+ tumor cells have enhanced proliferation compared to control cells. Treatment of the MMTV-
PyMT;Apc
Min/+ cells with an inhibitor of Src, a high dose of the JNK inhibitor (30 mM) or a combination of Src and JNK inhibitors for 12 h significantly
inhibited their BrdU incorporation, reducing it to levels similar to control cells (*p,0.05 MMTV-PyMT;Apc
Min/+ cells compared to control, PP2-treated,
and PP2/SP600125-treated cells).
doi:10.1371/journal.pone.0029339.g005
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metastasis is necessary to discriminate between these possibilities.
In addition to accelerating tumorigenesis in the PyMT model,
Apc mutation altered the tumor phenotype from solid carcinomas
to squamous adenocarcinomas. Interestingly, multiple models of
ectopic Wnt/b-catenin signaling in the mammary gland develop
squamous mammary tumors or areas of transdifferentiation
[8,11,13,14,15,45,46,47,48]. However, the histopathological
changes we observed cannot be attributed solely to Wnt/b-
catenin pathway activation since the basal activity in PyMT
tumors was not significantly changed in Apc-mutant cells. Although
a modest induction of Wnt/b-catenin activity is possible, we
previously published the importance of Wnt-independent APC
activities, such as regulation of apical-basal polarity and morpho-
genesis, in regulating lobuloalveolar development and the
occurrence of squamous metaplasia in mammary glands from
Apc
Min/+ mice [8]. Multiple signaling molecules are known to be
involved in squamous differentiation of the breast, including
SMAD4 [49], cyclin D1 [50], cyclin D3 [51], and JNK [52]. In
the PyMT;Apc
Min/+ model, we observed increased phosphorylation
of JNK (Figure 5A) without a change in cyclin D1 expression
(J.R.P., K.H.G., unpublished results). Although JNK was impli-
cated in squamous differentiation downstream of Wnt/b-catenin
activation [52], APC loss, independent of Wnt/b-catenin
signaling, could activate this pathway. Axin, another component
of the b-catenin destruction complex, induces JNK through a
Wnt-independent mechanism [53]. Some differences in tumor
histopathology in vivo were retained in the in vitro cell cultures.
Specifically, the Apc-mutant tumor cells had a more spread
morphology, enhanced cell-matrix interactions with fewer cell-cell
contacts. Hyperactivation of JNK has been demonstrated to be
responsible for a partial epithelial-mesenchymal transition (EMT)
and promoting cell survival [54]. These morphological changes
are also consistent with alterations directly in FAK-mediated
signaling. Subconfluent FAK
2/2 fibroblasts have a rounded
morphology and similar staining pattern of focal adhesion markers
to the MMTV-PyMT;Apc
+/+ cells [55]. Collectively, these data
suggest that the augmented JNK and FAK signaling observed in
the MMTV-PyMT;Apc
Min/+ cells may be responsible for the
morphological changes observed in vivo and in vitro.
The mechanisms responsible for increased tumor cell prolifer-
ation and decreased survival by APC inactivation are likely to be
more difficult to fully dissect. We found elevated FAK phosphor-
ylation, consistent with morphological changes observed and
recent data showing that conditional knockout of Apc in the
intestine results in a c-myc-dependent FAK up-regulation, which is
necessary for the increased proliferation and transformation of the
intestinal epithelium [56]. Since an increase in c-myc, or other
Wnt/b-catenin target genes, was not observed in Apc-mutant
tumors, it is important to consider alternative mechanisms by
which APC mutation mediates FAK activation. APC at the
leading edge of cells is required for directed cell motility [57,58]
and has been hypothesized to interact with integrins through its
association with both the actin and microtubule cytoskeleton [59].
Disruption of these interactions, particularly leading to changes in
actin or microtubule polymerization or dynamics, could perturb
FAK signaling, and current studies in the laboratory are aimed at
investigating this possibility. We also identified increased phos-
phorylation of Src (Tyr 416) and JNK (Thr183/Tyr185).
Interestingly, FAK autophosphorylation recruits Src to the focal
adhesions, where, through Rac activation, JNK and other
signaling molecules, are activated [60]. In human breast cancer,
FAK expression is correlated with phospho-Src (Tyr215) [61] and
poor prognosis [62]. Therefore, we hypothesize that APC
mutation increases FAK autophosphorylation to induce down-
stream signaling through Src and JNK. Like Src, previous studies
have demonstrated that mammary-specific FAK deletion protects
against MMTV-PyMT-driven tumors through inhibiting prolifer-
ation, and that autophosphorylation at Tyr397 is required for
tumor development [63]. Furthermore, loss of either Src or FAK
in mammary epithelial cells results in decreased proliferation in
PyMT-induced mammary hyperplasias and tumors [64,65]. Our
findings using inhibitors of Src and JNK suggest that hyperactiva-
tion of these signaling pathways is involved in the enhanced
proliferation resulting from Apc mutation. Although these studies
have focused on in vivo models, the results are likely to be relevant
to human breast cancer. The tumors that arise in these mice
resemble metaplastic carcinomas of the breast in humans, cancers
previously associated with APC down-regulation [3]. Our data
also suggest that the targeted inhibition of the signaling pathways
specifically hyper-activated downstream of APC mutation, such as
Src and JNK, may prove to provide a therapeutic benefit for these
cancers.
Supporting Information
Figure S1 LOH is not observed in mammary tumors
from MMTV-PyMT;Apc
Min/+ mice. Quantification of the
wildtype and Apc
Min alleles was determined in genomic DNA
isolated from tumors (n=6) and cell lines derived from the tumors
using a PCR-based assay as described [27]. The ratio of the Apc
+
to the Apc
Min bands was then quantified by densitometry. Controls
included DNA isolated from tails, normal intestine, a colon tumor
and normal (non-tumor) mammary gland from Apc
Min/+ mice. To
verify that intensity of the bands for each allele correlated to the
ratio, Apc
+/+ tail DNA was spiked with increasing concentrations of
Apc
Min/+ genomic DNA (at a ratio of 1:1, 1:3, and 1:7). As
expected, while the intensity of the Apc
Min band increased in a
dose-dependent manner, the Apc
+ band and the corresponding
ratio decreased. Mammary tumors from MMTV-PyMT;Apc
Min/+
mice, and cell lines derived from them, retain the Apc
+ allele.
(PDF)
Figure S2 Alterations in MMTV-PyMT-driven tumori-
genesis in the presence of the Apc
Min mutation are not
associated with Wnt/b-catenin pathway hyperactivation.
b-catenin localization and intensity were analyzed in MMTV-
PyMT;Apc
+/+ (n=4) and MMTV-PyMT;Apc
Min/+ (n=5) tumor
sections by IHC using an anti-b-catenin antibody as previously
described [25]. Data are shown as the percent of tumors with
positive staining for membrane, cytosolic, and nuclear b-catenin
with staining intensity on the x-axis. (A) No significant difference is
observed in membrane, cytosolic, or nuclear expression of b-
catenin in tumors isolated from the MMTV-PyMT;Apc
Min/+
animals compared to controls. Representative images of b-catenin
localization at the membrane (B, white arrows), cytosol (C, black
arrows), or nucleus (D, black arrows) are shown. The magnified
region in the inset is marked in each image by a hatched box.
Scale bar=50 mm.
(PDF)
Figure S3 A second set of cell lines isolated from
MMTV-PyMT;Apc
+/+ and MMTV-PyMT;Apc
Min/+ mice
show similar phenotypes. (A) IF with a b-catenin antibody
(green) and E-cadherin (red) antibody shows restricted localization
of both proteins to cell-cell contacts in the control cells (left panel).
In the Apc-mutant cells (right panel), junctional b-catenin and E-
cadherin are observed but b-catenin is also localized in a punctate
pattern in the cytosol or membrane. No nuclear accumulation of
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Scale bars=20 mm. (B) b-catenin/TCF reporter assays showed
little basal activity in both cell lines. SW480 cells were used as a
positive control. The data are shown as a ratio of normalized
TOPflash:FOPflash values. (C) Western blotting was performed
on total cell lysates from the tumor cell lines with antibodies to
detect total and phosphorylated forms of JNK, FAK and Src.
Increased phosphorylation of JNK, FAK, and Src is observed in
the MMTV-PyMT;Apc
Min/+ tumor cells compared to control cells.
(D) Tumor cell proliferation was assessed using BrdU incorpora-
tion and staining with an anti-BrdU antibody. Quantification
shows that, consistent with the in vivo studies, MMTV-PyMT;
Apc
Min/+ tumor cells have enhanced proliferation compared to
control cells. (E) IF with a phospho-FAK (Tyr 397) antibody
(green) shows increased expression in the tumors from MMTV-
PyMT;Apc
Min/+ mice (right panel) compared to the control tumors
(left panel). Nuclei are stained with Hoechst (blue). Scale
bars=20 mm.
(PDF)
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